Roy Cleeland

1.5k total citations
66 papers, 1.2k citations indexed

About

Roy Cleeland is a scholar working on Pharmacology, Epidemiology and Molecular Medicine. According to data from OpenAlex, Roy Cleeland has authored 66 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pharmacology, 25 papers in Epidemiology and 21 papers in Molecular Medicine. Recurrent topics in Roy Cleeland's work include Antibiotics Pharmacokinetics and Efficacy (26 papers), Antibiotic Resistance in Bacteria (21 papers) and Antimicrobial Resistance in Staphylococcus (10 papers). Roy Cleeland is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (26 papers), Antibiotic Resistance in Bacteria (21 papers) and Antimicrobial Resistance in Staphylococcus (10 papers). Roy Cleeland collaborates with scholars based in United States, Canada and Switzerland. Roy Cleeland's co-authors include E. Grunberg, Barbara Prosser, G. Beskid, W. F. DeLorenzo, Michael Krämer, James G. Christenson, Dennis D. Keith, Manfred Weigele, Silvano De Bernardo and W. Leimgruber and has published in prestigious journals such as The Journal of Immunology, Clinical Infectious Diseases and Biochemical and Biophysical Research Communications.

In The Last Decade

Roy Cleeland

65 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roy Cleeland United States 21 420 307 256 249 159 66 1.2k
T Une Japan 16 535 1.3× 414 1.3× 139 0.5× 234 0.9× 149 0.9× 33 1.3k
Pamela Hunter United States 13 292 0.7× 380 1.2× 189 0.7× 277 1.1× 168 1.1× 26 1.1k
A. R. English United States 16 271 0.6× 520 1.7× 283 1.1× 395 1.6× 242 1.5× 45 1.3k
Paul Actor United States 17 277 0.7× 320 1.0× 167 0.7× 177 0.7× 231 1.5× 72 988
H. H. Gadebusch United States 18 254 0.6× 219 0.7× 304 1.2× 159 0.6× 196 1.2× 63 952
Sachiko Gotô Japan 20 411 1.0× 346 1.1× 121 0.5× 247 1.0× 162 1.0× 92 1.1k
D. M. Ryan United Kingdom 16 184 0.4× 588 1.9× 369 1.4× 321 1.3× 186 1.2× 35 1.1k
Nobuo Kato Japan 23 627 1.5× 112 0.4× 303 1.2× 242 1.0× 123 0.8× 141 1.9k
L. Tybring Denmark 12 264 0.6× 392 1.3× 167 0.7× 238 1.0× 174 1.1× 24 917
J J Pocidalo France 23 231 0.6× 349 1.1× 673 2.6× 291 1.2× 332 2.1× 87 1.5k

Countries citing papers authored by Roy Cleeland

Since Specialization
Citations

This map shows the geographic impact of Roy Cleeland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roy Cleeland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roy Cleeland more than expected).

Fields of papers citing papers by Roy Cleeland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roy Cleeland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roy Cleeland. The network helps show where Roy Cleeland may publish in the future.

Co-authorship network of co-authors of Roy Cleeland

This figure shows the co-authorship network connecting the top 25 collaborators of Roy Cleeland. A scholar is included among the top collaborators of Roy Cleeland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roy Cleeland. Roy Cleeland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Morck, Douglas W., Kei Fong Lam, Merle S. Olson, et al.. (1994). Comparative evaluation of fleroxacin, ampicillin, trimethoprimsulfamethoxazole, and gentamicin as treatments of catheter-associated urinary tract infection in a rabbit model. International Journal of Antimicrobial Agents. 4. S21–S27. 21 indexed citations
3.
Rubin, Robert H., Eli Livni, John W. Babich, et al.. (1993). Pharmacokinetics of Fleroxacin as Studied by Positron Emission Tomography and [18F]Fleroxacin. The American Journal of Medicine. 94(3). 31S–37S. 4 indexed citations
4.
Thrupp, Lauri, Roy Cleeland, Ronald N. Jones, et al.. (1992). General Guidelines for Clinical Bacteriology. Clinical Infectious Diseases. 15(Supplement_1). S339–S346. 3 indexed citations
5.
Fischman, Alan J., Eli Livni, John W. Babich, et al.. (1992). Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography. Antimicrobial Agents and Chemotherapy. 36(10). 2286–2292. 29 indexed citations
6.
Prosser, Barbara, et al.. (1991). In vitro Activity of Ceftriaxone and Amikacin against <i>Pseudomonas aeruginosa</i>. Chemotherapy. 37(2). 93–97. 2 indexed citations
7.
Beskid, G., James G. Christenson, Roy Cleeland, et al.. (1990). Cephalosporin 3'-quinolone esters with a dual mode of action. Journal of Medicinal Chemistry. 33(1). 77–86. 48 indexed citations
8.
Beskid, G., et al.. (1990). In vivo Evaluation of a Dual-Action Antibacterial, Ro 23-9424, Compared to Cefotaxime and Fleroxacin. Chemotherapy. 36(2). 109–116. 20 indexed citations
9.
Olson, Merle S., Jens Nickel, Antoine E. Khoury, et al.. (1989). Amdinocillin Treatment of Catheter-Associated Bacteriuria in Rabbits. The Journal of Infectious Diseases. 159(6). 1065–1072. 28 indexed citations
10.
Laux, David C., et al.. (1988). Radiochemical method for evaluating the effect of antibiotics on Escherichia coli biofilms. Antimicrobial Agents and Chemotherapy. 32(5). 770–772. 7 indexed citations
11.
Behl, Christian, et al.. (1988). Effect of Medium Chain Glycerides on Enteral and Rectal Absorption of β-Lactam and Aminoglycoside Antibiotics. Chemotherapy. 34(4). 272–276. 12 indexed citations
12.
Prosser, Barbara, et al.. (1987). Method of evaluating effects of antibiotics on bacterial biofilm. Antimicrobial Agents and Chemotherapy. 31(10). 1502–1506. 165 indexed citations
13.
Beskid, G., James G. Christenson, Roy Cleeland, W. F. DeLorenzo, & Patrick W. Trown. (1981). In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin. Antimicrobial Agents and Chemotherapy. 20(2). 159–167. 34 indexed citations
14.
Krämer, Michael, et al.. (1979). 5'-deoxy-5-fluorouridine-a New orally active antitumor agent. Comparative activity with 5-fluorouracil, 2'- deoxy-5-fluorouridine and ftorafur against transplant- able tumors in mice and rats. Abstr.. The Mouseion at the JAXlibrary (Jackson Laboratory). 20. 12 indexed citations
15.
Krämer, Michael, Roy Cleeland, & E. Grunberg. (1976). Antiviral Activity of 10-Carboxymethyl-9-Acridanone. Antimicrobial Agents and Chemotherapy. 9(2). 233–238. 41 indexed citations
16.
Weigele, Manfred, Silvano De Bernardo, W. Leimgruber, Roy Cleeland, & E. Grunberg. (1973). Fluorescent labeling of proteins. A new methodology. Biochemical and Biophysical Research Communications. 54(3). 899–906. 63 indexed citations
17.
Catlin, Don H., Roy Cleeland, & E. Grunberg. (1973). A Sensitive, Rapid Radioimmunoassay for Morphine and Immunologically Related Substances in Urine and Serum. Clinical Chemistry. 19(2). 216–220. 31 indexed citations
18.
Sugg, John Y. & Roy Cleeland. (1962). Differences in Trypsin Susceptibility Among Influenza Viruses and Relationship of the Susceptibility to the Antigenic Type of Subtype of the Virus. The Journal of Immunology. 88(3). 369–376. 3 indexed citations
19.
Cleeland, Roy & John Y. Sugg. (1960). Effect of Trypsin on a Susceptible Strain of Influenza A Virus,. The Journal of Immunology. 85(5). 539–545. 2 indexed citations
20.
Cleeland, Roy & Albert P. McKee. (1958). Antigenic Variation of Asian Influenza Virus.. Experimental Biology and Medicine. 99(2). 371–374. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T Une Breakdown of academic impact, for papers by Pamela Hunter Breakdown of academic impact, for papers by A. R. English Breakdown of academic impact, for papers by Paul Actor Breakdown of academic impact, for papers by H. H. Gadebusch Breakdown of academic impact, for papers by Sachiko Gotô Breakdown of academic impact, for papers by D. M. Ryan Breakdown of academic impact, for papers by Nobuo Kato Breakdown of academic impact, for papers by L. Tybring Breakdown of academic impact, for papers by J J Pocidalo
Rankless by CCL
2026